Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

om and www.sedar.com. About YM BioSciences YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, n
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
11. Cell Biosciences to Acquire Convergent Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... and biochemistry at The University of Texas at Austin, ... with Professor William Moerner of Stanford University. , The ... Tamir, was given to the two scientists for their ... and imaging. , The $100,000 prize will be presented ...
... service revenue of $238.7 million grows 32% year-over-year, - Operating ... - Backlog increases 41% ... - Net quarterly book-to-burn ratio equates ... PRXL ) today announced its financial results for the,second quarter ended ...
... of Family Cord Blood Banks, LOS ANGELES, ... of California Cryobank, today announced that its co-founder ... appointed to the Department,of Health and Human Services, ... on Blood Stem Cell Transplantation,(ACBSCT). Through his appointment, ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 2Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... A new grant from the National Institute of Biomedical ... of Health (NIH), will provide funding for University of ... novel bioreactor system that will control mechano-electrochemical environment for ... properties of engineered tissues. The two-year, $735,000 grant will ...
... Il. A key statistic that consumer groups and ... national rankings can be misleading, researchers report in a new ... number above 1.0 indicates a hospital had more deaths than ... were fewer than the expected number of deaths. The ...
... Aquaculture, once a fledgling industry, now accounts for 50 percent ... by an international team of researchers. And while the industry ... significant strain on marine resources by consuming large amounts of ... authors conclude. Their findings are published in the Sept. 7 ...
Cached Biology News:University of Miami receives NIH grant to support novel technology for tissue engineering 2Treating bone loss in breast cancer survivors 2Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
ANTI GELSOLIN...
...
... is intended for the derivation of ... in serum-free conditions. ... Clonal Grade Medium Basal Medium ... Trypsin Solution Gelatin Solution Complete Freezing ...
Template and primers for preparation of internal control spots...
Biology Products: